Health Care • Biotechnology: Pharmaceutical Preparations
$3.51 ▲ +0.51
(+16.83%)
MKT CAP: $54.1M • VOL: 547.0K
52W L $2 52W H $6
ROARABLE / RQD
D • 50/100
PIOTROSKI
5 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$3
MEDIAN
$4
MEAN
$4
HIGH
$5
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE HYPD TAPE
HYPD // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $4.25 | $4.04 | 2025-02-14 | $3.19 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $4.42 | $4.14 | 2025-02-06 | $3.30 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $4.00 | $3.86 | 2025-01-29 | $3.37 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $3.58 | — | 2025-01-17 | $3.44 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $3.09 | $3.33 | 2025-01-09 | $3.12 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $4.18 | $3.65 | 2024-12-18 | $3.05 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $3.40 | $3.55 | 2024-12-04 | $3.26 | -4.3% | 48% | C |